reported side effects of glimepiride/pioglitazone
hypoglycemia
weight gain
other side effects
edema
nausea
comprehensive list of adverse effects
common adverse reactions
upper respiratory tract infections
accidental injury
combined edema/peripheral edema
pioglitazone-sulfonylureavery
lower leg edema
pioglitazone
edema
cardiac failure
chest pain
pioglitazone
edema
pitting edema
fluid retention
combination therapy
pioglitazone monotherapy trials
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
weeks
pioglitazone in combination with a sulfonylurea
weeks
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
study in patients with nyha class
heart failure
percentage of patients
experiencing chf progression during the study
patients
receiving pioglitazone
n =-rrb-
glyburide
n =-rrb-
proactive trial
study in patients with type diabetes
history of macrovascular disease
pioglitazone mg
day
received placebo in addition
standard of care
edema
patients
pioglitazone
n =-rrb-
placebo
n =-rrb- patients
treatment-emergent adverse events
least hospitalized congestive heart failure event
patients
receiving pioglitazone
patients
receiving placebo
primary objective of the
year
proactive trial
effect of pioglitazone on mortality
macrovascular morbidity in high-risk patients
significant difference between pioglitazone
placebo/standard care
time
first occurrence
first event
all-cause mortality
nonfatal myocardial infarction
mi
including
silent mi
stroke
acute coronary syndrome
cardiac intervention
coronary artery bypass grafting
percutaneous intervention
major leg amputation above the ankle
bypass surgery
revascularization in the leg
total of patients
receiving pioglitazone
least event
patients
receiving placebo/standard care
postmarketing reports of congestive heart failure
patients
pioglitazone
reports
patients
history of a known history of heart disease
concomitant insulin use
pioglitazone
alt values
times
upper limit of normal
uln
postmarketing reports
hepatic failureglimepiride
elevated alt
ulnpostmarketing reports
liver function impairment
cholestasis
jaundice
hepatitis
liver failure
hepatic porphyria reactions
disulfiram-like reactions
been postmarketing reports of serious allergic reactions in patients
receiving glimepiride
anaphylaxis
angioedema
stevens-johnson syndrome
dyspnea
hypotension
shock
clinical trials
allergic reactions
pruritus
erythema
urticaria
morbilliform
maculopapular eruptions
patients
receiving glimepiride
continued treatment
glimepiride
allergic reactionspostmarketing reports
serious allergic reactions
us fda
released results
review of pioglitazone
bladder cancer
data
use of this drug
increase risk of bladder cancer
year
prospective cohort study in diabetic patients
manufacturer
n
users
n
users
diagnosed cases of bladder cancer
users
cases
users
adjusted hazard ratio
hr
pioglitazone use
increased risk
hr
confidence interval
modest trend towards higher risk
increasing duration
trend
interim
year
year
found weaker associations
studies
significant association between exposure
drug
bladder cancer
association between cumulative dose
cumulative duration of exposure
bladder cancer
drug
increase in the risk of urinary bladder tumors
insufficient data
drug
tumor promoter for urinary bladder tumors
pioglitazone
bladder cancer
pioglitazone
frequency
resumption of ovulation in premenopausal
anovulatory women
hormonal imbalance glimepiride
postmarketing reports
hyponatremia
syndrome of inappropriate antidiuretic hormone secretion
siadh
siadh
been reported postmarketing in patients
receiving glimepiride
patients
other medications
medical conditions
hyponatremia
increase release of antidiuretic hormone
pioglitazone
postmarketing reports
new
worsening
worsening diabetic macular edema
decreased visual acuity
macular edema
postmarketing experience in diabetic patients
taking pioglitazone
patients
blurred vision
decreased visual acuity
patients
routine ophthalmologic examination
patients
peripheral edema at the time
macular edema
patients
improvement
macular edema after discontinuation
causal relationship between pioglitazone
macular edema
pioglitazone
dose-related weight gain
combination therapy
mechanism of weight gain
combination of fluid retention
fat accumulation
pioglitazone monotherapy trials
weight increases of kg
kg
kg
patients
receiving mg
mg
mg of pioglitazone
weeks
pioglitazone in combination with a sulfonylurea
weeks
weight increases of kg
kg
kg
patients
receiving mg
mg
mg of pioglitazone
prospective pioglitazone
clinical trial in macrovascular events
trial
median change in body weight in patients
pioglitazone
n =-rrb-
placebo
n =-rrb-
kg
kg
median exposure
drug
years
pioglitazone-sulfonylureavery
hypoglycemia
weight increase
pioglitazone-sulfonylureavery
upper
respiratory tract infection
sinusitis
pharyngitispioglitazone
upper
respiratory tract infection
pioglitazone-sulfonylureafrequency
anemiapioglitazone
frequency
decreases in hemoglobin
hematocritglimepiride
postmarketing reports
hemolytic anemia
leukopenia
agranulocytosis
aplastic anemia
pancytopenia
thrombocytopenia
thrombocytopenia purpura
laboratory findings
shown decreases in hemoglobin
hematocrit with pioglitazone therapy
hemoglobin values
pioglitazone
treated patients
placebo-treated patients
changes
first months
changes
increased plasma volume
significant hematologic effects
pioglitazone-sulfonylureacommon
diarrhea
nausea
pioglitazone-sulfonylureacommon
headache
dizziness
pioglitazone-sulfonylureacommon
limb painpioglitazone
myalgia
pain in extremity
painfrequency
elevated creatine phosphokinase
cpk
elevations in cpk
protocol-specified measurement of cpk in pioglitazone
clinical trials
isolated elevation
times
upper limit of normal
patients
elevations
clinical sequelae
relationship
drug therapy
glimepiride
postmarketing reports
porphyria cutanea tarda
photosensitivity reactions
allergic vasculitis
pioglitazone-sulfonylureacommon
urinary tract infection
anxiety
bladder pain
cloudy urine
blurred vision
chills
cold sweats
coma
confusion
cool, pale skin
depression
burning
painful urination
fast heartbeat
frequent urge
headache
increased hunger
increased weight
side pain
nausea
nightmares
seizures
shakiness
slurred speech
swelling of the feet
lower legs
unusual tiredness
weakness
accidental injury
loss of appetite
pain
swelling in the arms
legs without any injury
pale skin
stomach pain
troubled breathing with exertion
unusual bleeding
bruising
vomiting
weight loss
yellow eyes
skin
body aches
pain
cough
diarrhea
difficulty with moving
dryness
soreness of the throat
ear congestion
fever
hoarseness
joint pain
loss of voice
muscle
cramping
muscle pains
stiffness
runny nose
sneezing
stuffy nose
swollen joints
tender
swollen glands in the neck
tooth disorder
trouble swallowing
voice changes
dizziness
itching skin
lack
loss of strength
skin rash